Q-omics provides the consensus-scored MYOCD profile across patient tissues and cancer cell-line models. MYOCD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYOCD is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MYOCD RNA expression shows 17,202 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where MYOCD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYOCD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYOCD survival associations across molecular data types. MYOCD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYOCD RNA expression–survival associations across cancer types. High MYOCD expression shows unfavorable associations in KIRP, SCLC, LUSC and UVM, but favorable associations in KIRC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYOCD RNA expression.
This table summarizes MYOCD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MYOCD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYOCD shows lower tumor expression in BLCA, COAD, KICH, LUAD, LUSC and KIRP. The BLCA box plot shows higher MYOCD RNA expression in normal versus tumor tissue (log2 FC = −5.098, t-test p < 0.001).
This table shows molecular features associated with MYOCD in patient tissues and cancer cell lines. In patient samples, MYOCD shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYOCD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
